Kinsella on Liberty Podcast: Episode 469.

This is my appearance on Adam Haman’s podcast and Youtube channel, Haman Nature (Haman Nature substack), episode HN 149, “Free The DRUGS! Stephan KINSELLA Counters Economist Alex TABARROK On Price Controls | Hn 149” (recorded June 25,  2025).

Tabarrok seems to be generally pro-free market and an Austrian or fellow traveler. However, although he sometimes criticizes existing IP law, he is not opposed to intellectual property (IP), unlike all the cool Austro-libertarians. (( The Death Throes of Pro-IP Libertarianism. )) And he often proposes changes to IP law—sometimes outrageously goofy ones, such as his truly insane idea of replacing the patent system with $3.5 trillion worth of taxpayer subsidies (if you take his logic for a taxpayer funded "medical innovation price fund" to its limit apply it to all forms of patented innovation and other forms of IP like copyright) (( $30 Billion Taxfunded Innovation Contracts: The “Progressive-Libertarian” Solution; Libertarian Favors $80 Billion Annual Tax-Funded “Medical Innovation Prize Fund; What's Worse: $80 Billion or $30 Million?. )) or based on simplistic assertions or confusions like the idea that we can empirically know that we are on the "wrong side" of the optimal patent term length on his ridiculous "Tabarrok Curve." (( Tabarrok: Patent Policy on the Back of a Napkin; The Overwhelming Empirical Case Against Patent and Copyright; Optimal Patent and Copyright Term Length. ))

So even though he's not against IP and thus not a very good libertarian, and he's not a Misesian since he seems to think utility is cardinal, measurable, and knowable, (( "The Problem with Intellectual Property" (2025), Part III.B.2. )

Shownotes, links, grok summary, and transcript below.

https://youtu.be/gNRsjF3UXT4?si=2T9-4aE3cMPRoMD1

GROK SUMMARY:
In the Haman Nature episode featuring patent attorney and libertarian legal theorist Stephan Kinsella, hosted by Adam Haman, the discussion centers on the high cost of prescription drugs in the United States and the misconceptions surrounding proposed solutions, including critiques of arguments made by economist Alex Tabarrok. Kinsella challenges the notion that former President Trump’s executive order would effectively lower drug prices, arguing that the issue stems from a complex interplay of government regulations, subsidies, and intellectual property (IP) laws, particularly pharmaceutical patents. He disputes the idea that other countries "free ride" on a supposed U.S. "free market" system, emphasizing that the U.S. pharmaceutical industry is far from a free market due to patent-driven monopolies that inflate prices and restrict competition. Kinsella’s critique, informed by his extensive work on IP (e.g., his discussions in the Kinsella on Liberty Podcast, Episode 469, and articles on c4sif.org), highlights how these monopolies distort market dynamics and prevent natural price equalization through arbitrage across borders.
The conversation also addresses Tabarrok’s arguments, as discussed in his interview with Bob Murphy, particularly the concept of the "Tabarrok Curve," which posits an optimal level of IP protection to maximize innovation. Kinsella rejects this, asserting that pharmaceutical patents are not the definitive case for IP necessity, as they often delay generic drugs, skew research toward profitable rather than essential medicines, and raise costs for consumers. He points to industries like fashion and software, which thrive without heavy patent reliance, to argue that innovation does not require IP protections (referencing his critiques in “Tabarrok, Cowen, and Douglass North on Patents” and “Software Patents Bad, Pharmaceutical Patents Good?” on c4sif.org). Additionally, Kinsella dismisses Tabarrok’s proposal for a tax-funded prize system to replace IP as an unlibertarian solution that substitutes o...